started · updated
GeoVax Advances GEO-MVA Vaccine Study and Reports Q2 2026 Results
GeoVax Labs, Inc. announced its financial results for the second quarter ended June 30, 2026 and provided a business update. The company said it is on track to launch a pivotal GEO-MVA immunobridging study in the fourth quarter of 2026 under an expedited regulatory pathway agreed with the European Medicines Agency. Preparations include clinical study readiness, manufacture of cGMP trial material, and development of the AGE1® continuous‑cell manufacturing platform for future commercial‑scale production. GeoVax also reported progress on its Gedeptin immuno‑oncology program, which aims to enhance checkpoint‑inhibitor therapy. CEO David A. Dodd emphasized that completing the GEO-MVA study is a critical value‑creating milestone and highlighted the company’s commitment to diversified vaccine supply for public‑health preparedness and biodefense.
Entities
David A. Dodd · European Medicines Agency · GEO-MVA · Gedeptin · GeoVax Labs, Inc.
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 2 SOURCES] GeoVax is developing the AGE1® continuous cell‑line manufacturing platform for future commercial‑scale MVA vaccine production.
- [● 2 SOURCES] CEO David A. Dodd said the GEO‑MVA program is a key value‑creating milestone for the company.
- [● 2 SOURCES] GeoVax advanced clinical study readiness, manufacturing preparedness, and utilization of previously manufactured cGMP trial material.
- [● 2 SOURCES] GeoVax continued advancing its Gedeptin immuno‑oncology platform aimed at enhancing checkpoint inhibitor therapy.
- [● 2 SOURCES] GeoVax plans to initiate a pivotal GEO‑MVA immunobridging study in the fourth quarter of 2026.
- [● 2 SOURCES] GeoVax engaged with government and public entities to support diversified MVA vaccine supply for public‑health preparedness and biodefense.
- [● 2 SOURCES] GeoVax Labs reported its second‑quarter 2026 financial results for the quarter ended June 30, 2026.
- [● 2 SOURCES] The GEO‑MVA study will follow an expedited regulatory pathway after scientific advice from the European Medicines Agency.